Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Non-Small-Cell Lung 6Neoplasm, Residual 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Maintenance × Clear all
NCT04542824 2026-05-05

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02063685 2022-06-21

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Fondazione Italiana Linfomi - ETS

Phase 3 Completed
807 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡